mTOR inhibitors, currently used in the treatment of TSC (tuberous sclerosis complex) and other mTOR-related pathologies, have shown promise in reducing seizure frequency and severity by normalizing synaptic protein synthesis and reducing aberrant neuronal growth. This evidence concerns the gene MTOR and tuberous sclerosis.